F. Mansour-Ghanaei, Kourosh Mojtahedi, F. Joukar, Seyyed-Hossein Seyyed-Nezhad Fahim, S. Yeganeh, M. Asgharnezhad, Saba Fakhrieh Asl
{"title":"褪黑素、二甲双胍和熊去氧胆酸对非酒精性脂肪肝的影响:一项随机、双盲对照试验","authors":"F. Mansour-Ghanaei, Kourosh Mojtahedi, F. Joukar, Seyyed-Hossein Seyyed-Nezhad Fahim, S. Yeganeh, M. Asgharnezhad, Saba Fakhrieh Asl","doi":"10.21608/bfsa.2023.177224.1590","DOIUrl":null,"url":null,"abstract":"Objective: This study was to investigate and compare the effect of melatonin, metformin, and ursodeoxycholic acid (UDCA) on non-alcoholic fatty liver disease(NAFLD). Methods : In this randomized double-blinded clinical trial, 120 patients with NAFLD who had been referred to Gastrointestinal and Liver Diseases Research Center, Rasht, Iran, between September 2015 and January 2016. Patients were randomly assigned to 4 groups. Each group received melatonin, metformin, UDCA, or placebo in addition to a weight loss diet for 3 months. Results : A significant reduction was observed in levels of steatosis, alanine aminotransferase, alkaline phosphatase, body weight, BMI, waist circumstance and triacylglycerol among participants in groups with metformin or melatonin administration. In addition a significant decrease in fasting plasma glucose, and total cholesterol concentration was detected following metformin and UDCA administration, respectively. Conclusions : The present study suggests that the addition of metformin or melatonin to a low-caloric diet may be effective in the treatment of patients with NAFLD.","PeriodicalId":345040,"journal":{"name":"Bulletin of Pharmaceutical Sciences. Assiut","volume":"36 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The effect of melatonin, metformin and ursodeoxycholic acid on non-alcoholic fatty liver disease: A randomized, double-blinded controlled trial\",\"authors\":\"F. Mansour-Ghanaei, Kourosh Mojtahedi, F. Joukar, Seyyed-Hossein Seyyed-Nezhad Fahim, S. Yeganeh, M. Asgharnezhad, Saba Fakhrieh Asl\",\"doi\":\"10.21608/bfsa.2023.177224.1590\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: This study was to investigate and compare the effect of melatonin, metformin, and ursodeoxycholic acid (UDCA) on non-alcoholic fatty liver disease(NAFLD). Methods : In this randomized double-blinded clinical trial, 120 patients with NAFLD who had been referred to Gastrointestinal and Liver Diseases Research Center, Rasht, Iran, between September 2015 and January 2016. Patients were randomly assigned to 4 groups. Each group received melatonin, metformin, UDCA, or placebo in addition to a weight loss diet for 3 months. Results : A significant reduction was observed in levels of steatosis, alanine aminotransferase, alkaline phosphatase, body weight, BMI, waist circumstance and triacylglycerol among participants in groups with metformin or melatonin administration. In addition a significant decrease in fasting plasma glucose, and total cholesterol concentration was detected following metformin and UDCA administration, respectively. Conclusions : The present study suggests that the addition of metformin or melatonin to a low-caloric diet may be effective in the treatment of patients with NAFLD.\",\"PeriodicalId\":345040,\"journal\":{\"name\":\"Bulletin of Pharmaceutical Sciences. Assiut\",\"volume\":\"36 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Pharmaceutical Sciences. Assiut\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/bfsa.2023.177224.1590\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Pharmaceutical Sciences. Assiut","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/bfsa.2023.177224.1590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The effect of melatonin, metformin and ursodeoxycholic acid on non-alcoholic fatty liver disease: A randomized, double-blinded controlled trial
Objective: This study was to investigate and compare the effect of melatonin, metformin, and ursodeoxycholic acid (UDCA) on non-alcoholic fatty liver disease(NAFLD). Methods : In this randomized double-blinded clinical trial, 120 patients with NAFLD who had been referred to Gastrointestinal and Liver Diseases Research Center, Rasht, Iran, between September 2015 and January 2016. Patients were randomly assigned to 4 groups. Each group received melatonin, metformin, UDCA, or placebo in addition to a weight loss diet for 3 months. Results : A significant reduction was observed in levels of steatosis, alanine aminotransferase, alkaline phosphatase, body weight, BMI, waist circumstance and triacylglycerol among participants in groups with metformin or melatonin administration. In addition a significant decrease in fasting plasma glucose, and total cholesterol concentration was detected following metformin and UDCA administration, respectively. Conclusions : The present study suggests that the addition of metformin or melatonin to a low-caloric diet may be effective in the treatment of patients with NAFLD.